Using PET imaging to test a new treatment for protecting brain connections in Alzheimer's and related dementias.
Official title: PET Imaging to Evaluate a Novel Chemokine Antagonist to Protect Synapses in ADRD
Funded at Creative Bio-Peptides, INC. · NIH-10934595 · Data updated 2026-11-12
This study is testing a new treatment called RAP-103 to see if it can help protect brain connections in people with Alzheimer's disease and similar conditions, using special brain scans to check if it can stop damage and improve thinking skills.
Quick facts
| Grant type | Sbir 1 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Creative Bio-Peptides, INC. NIH-funded |
| Lab location | 1 site (Potomac, United States) |
| Project start | September 30, 2023 |
| Project end | June 30, 2025 |
| Funding year | 2024 |
| Award (this year) | $175,116 |
| NIH project number | 5R43AG085779-02 |
| Project ID | NIH-10934595 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are individuals aged 65 and older who are experiencing symptoms of Alzheimer's disease or related dementias.
✕Less likely to help
Patients who are younger than 65 or do not have Alzheimer's disease or related dementias may not benefit from this research.
What this research studies
This research investigates a novel chemokine antagonist, RAP-103, aimed at protecting synapses in patients with Alzheimer's disease and related dementias (ADRD). By utilizing PET imaging, the study will evaluate how effectively RAP-103 can prevent synapse loss caused by toxic proteins associated with these conditions. The approach focuses on blocking the activation of certain proteins that lead to cognitive decline, with the hope of reversing damage and improving brain function. Patients will be monitored for changes in brain activity and cognitive performance throughout the study.
Why it matters
Potential benefit: If successful, this research could lead to new treatments that significantly slow down or even reverse cognitive decline in patients with Alzheimer's and related dementias.
How similar studies have gone: Previous research has shown promise in using similar approaches to protect synapses and improve cognitive function, suggesting potential for success in this novel application.
Where this research is happening
-
Creative Bio-Peptides, INC.
Potomac, United States Active
Researchers
- Principal investigator: Ruff, Michael R — Creative Bio-Peptides, INC.
- Study coordinator: Ruff, Michael R
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.